Focused On-demand Library for Ribonuclease H1

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

Our top-notch dedicated system is used to design specialised libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.

Our library distinguishes itself through several key aspects:

The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

partner

Reaxense

upacc

O60930

UPID:

RNH1_HUMAN

Alternative names:

Ribonuclease H type II

Alternative UPACC:

O60930; B3KQU4; O60523; O60857; Q57Z93; Q5U0C1; Q6FHD4

Background:

Ribonuclease H1, also known as Ribonuclease H type II, plays a pivotal role in cellular mechanisms by specifically degrading the RNA of RNA-DNA hybrids. Its activity is crucial for maintaining genomic stability by facilitating RNA polymerase II transcription termination and preventing R-loop RNA-DNA hybrid formation, which can occur at G-rich pause sites downstream of the poly(A) site.

Therapeutic significance:

The protein is linked to Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal recessive 2, a condition characterized by muscle weakness, exercise intolerance, and signs of spinocerebellar ataxia. Understanding the role of Ribonuclease H1 could open doors to potential therapeutic strategies for this and related mitochondrial myopathies.